Medtronic Study Detects Gene Associated with Sudden Cardiac Death
Medtronic plc (NYSE: MDT) today announced first-of-its-kind findings from two independent studies that have identified a gene associated with life-threatening abnormal heart rhythms. The study results were presented in a hotline session at the 2015 European Society of Cardiology (ESC) Congress in London. The studies evaluated genetic "markers" to determine which gene abnormalities may be associated with dangerous heart rhythms that can lead to sudden cardiac death (SCD). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 31, 2015 Category: Cardiology Source Type: news
European Guidelines Say "Radial First"
Today the European Society of Cardiology (ESC) gave the highest recommendation to the radial (wrist) approach for catheter-based interventions in patients with acute coronary syndromes (ACS). The "ACS without persistent ST-segment elevation (NSTE-ACS) guidelines," drafted by an international multidisciplinary Task Force, were introduced as part of this year's annual European Congress of Cardiology meeting, and are now published online. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 30, 2015 Category: Cardiology Source Type: news
Medtronic Moves into Mitral Valve Replacement
This morning, Medtronic plc (NYSE: MDT) announced it has agreed to acquire privately-held device company Twelve, Inc., based in Redwood City, California. Twelve has been developing a transcatheter mitral valve replacement device (TMVR) which is just beginning its first clinical pilot study, "Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation." Medtronic "has agreed to pay up to $458 million for Twelve including $408 million at closing and $50 million on achievement of CE Marking. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 25, 2015 Category: Cardiology Source Type: news
WomenHeart To Host First National Policy & Science Summit On Women's Cardiovascular Health
WomenHeart: The National Coalition for Women with Heart Disease today announced that it will host the first National Policy & Science Summit on Women's Cardiovascular Health, October 26-27, 2015 in Washington, DC. "The Summit is a game changer for the field of women's cardiovascular health," said Mary E. McGowan, CEO of WomenHeart. "Leaders in this field and patients are meeting to address the lack of sufficient policy, programs and funding for a disease that continues to debilitate and kill more women than all cancers combined." (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 20, 2015 Category: Cardiology Source Type: news
Medtronic Launches the Entrust™ Delivery System in the United States
Medtronic plc (NYSE: MDT) today announced the launch of its Entrust™ delivery system in the United States. The new Entrust delivery system enables physicians to place Medtronic's EverFlex™ self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 12, 2015 Category: Cardiology Source Type: news
Mount Sinai Launches TWILIGHT: Is Ticagrelor Alone Superior to DAPT Post-PCI?
Today Mount Sinai Medical Center in New York announced the launch of a new and very large randomized clinical trial to test the safety and efficacy of ticagrelor alone versus ticagrelor and aspirin together in high risk PCI patients. The international study, called TWILIGHT, aims to enroll 9,000 patients at 100 sites in the U.S., Canada, Europe, South America, and Asia. The study is being funded by AstraZeneca, the manufacturer of the blood-thinner ticagrelor (brand name Brilinta). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 12, 2015 Category: Cardiology Source Type: news
FDA Approves New Repositionable and Recapturable CoreValve from Medtronic
Today the FDA approved Medtronic's (NYSE: MDT) next-generation CoreValve Evolut R System for severe aortic stenosis patients who are at high or extreme risk for surgery. The Evolut R is the first and only recapturable and repositionable TAVR system available in the United States. In addition, the Evolut R system is offers a 14F delivery system, the narrowest profile currently available, and may reduce the type of vascular access complications that can occur with these larger devices. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 23, 2015 Category: Cardiology Source Type: news
Medtronic Initiates U.S. Launch of Fortrex™ PTA Balloon
Medtronic plc (NYSE: MDT) announced today the launch of the Fortrex™ over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex PTA balloon catheter utilizes a high pressure balloon to break up the blockages and open the vessels to help maintain arteriovenous (AV) access in the peripheral vascular system. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 14, 2015 Category: Cardiology Source Type: news
Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation
Medtronic plc (NYSE:MDT) today announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a unique, phased clinical program studying renal denervation in uncontrolled hypertension. This announcement follows investigational device exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The program will begin with two global studies designed to address the confounding factors encountered in the SYMPLICITY HTN-3 clinical trial, including medication, patient population and procedural variability, to ensure the clinical potential of the therapy is evaluated. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 10, 2015 Category: Cardiology Source Type: news
Global Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety Measures in Wide Range of Patients
Medtronic plc (NYSE: MDT) revealed today the first safety data on its Micra® Transcatheter Pacing System (TPS). In the largest reported sample of a transcatheter pacing system to date, the first 140 patients in the Medtronic Micra TPS Global Clinical Trial showed 100 percent were successfully implanted with the Micra TPS. The data were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 9, 2015 Category: Cardiology Source Type: news
Global Clinical Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety and Performance Measures
Medtronic plc (NYSE: MDT) today announced study results of its Micra® Transcatheter Pacing System (TPS), which demonstrated that the miniaturized pacemaker has met its initial safety and performance measures. In the largest report to date of a transcatheter pacing system, 100 percent of the first 140 patients who received the Micra TPS experienced a successful implant procedure, and mean electrical pacing measurements at all patient visits (one- and three--month follow up) were within expected ranges. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 9, 2015 Category: Cardiology Source Type: news
FDA OK for St. Jude to Resume Portico TAVR Trial
Today St. Jude Medical announced FDA approval to resume their U.S. IDE trial for the Portico Transcatheter Aortic Valve System. The trial had been put on pause back in September 2014 due to safety concerns. According to St. Jude's press release (below) both a company and independent review of the data have concluded that this reduced leaflet mobility is "a class effect," seen in all TAVR devices, as well as surgical valves. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 4, 2015 Category: Cardiology Source Type: news
Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial Disease Shows Strong Results in Long Lesions
Presented for the first time today at EuroPCR during the "Hot line" session on "Peripheral interventions," new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic plc (NYSE: MDT) successfully treated long lesions in the superficial femoral and popliteal arteries. Prof. Dierk Scheinert, chairman of the division for interventional angiology at University-Hospital Leipzig in Germany, presented 12-month results for 157 patients enrolled in the IN.PACT Global Study's long lesion imaging cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 3, 2015 Category: Cardiology Source Type: news
Ferdinand Kiemeneij and Shigeru Saito Honored at EuroPCR for Contributions to Transradial PCI
This year's EuroPCR meeting, the world-leading course in interventional medicine, honored two pioneers of the transradial (wrist) approach for coronary catheterization and intervention (TRI): Dr. Ferdinand Kiemeneij from The Netherlands and Dr. Shigeru Saito from Japan. Both have received the 2015 Ethica Award, bestowed by the PCR Board and EuroPCR Course Directors to remarkable individuals who have significantly contributed to the field of cardiovascular intervention as teachers, innovators, scientists, care providers, or pioneers. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 21, 2015 Category: Cardiology Source Type: news
Medtronic Begins Enrollment in Feasibility Study of Valiant 'Mona LSA' Branch Thoracic Stent Graft System
Medtronic plc (NYSE: MDT) announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery (LSA). Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 21, 2015 Category: Cardiology Source Type: news
